Statistics for Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging
Total visits
| views | |
|---|---|
| Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging | 67 |
Total visits per month
| views | |
|---|---|
| January 2024 | 0 |
| February 2024 | 0 |
| March 2024 | 0 |
| April 2024 | 0 |
| May 2024 | 0 |
| June 2024 | 1 |
| July 2024 | 0 |
File Visits
| views | |
|---|---|
| Lowe2021Donanemab-CCBY.pdf | 1380 |
Top country views
| views | |
|---|---|
| United States | 58 |
| China | 1 |
| India | 1 |
| South Korea | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 42 |
| Ann Arbor | 5 |
| Ashburn | 1 |
| Baltimore | 1 |
| Cambridge | 1 |
| Fairfield | 1 |
| Houston | 1 |
| Hyderabad | 1 |
| Lake Mary | 1 |
| Mount Laurel | 1 |
| Reston | 1 |
| Seodaemun-gu | 1 |
| Tustin | 1 |
| Washington | 1 |